DUBLIN–(BUSINESS WIRE)–The “Colorectal
Cancer Therapeutics: Global Markets” report has been added to ResearchAndMarkets.com’s
offering.
This report is a business analysis that examines market trends for
colorectal cancer therapeutics.
This report captures colorectal cancer therapeutics market revenue for
different regions by treatment type, i.e., chemotherapy, targeted
therapy and immunotherapy used for treating the disease. A detailed
colorectal cancer therapeutics market analysis covers the regions of
North America, Europe, Asia-Pacific, and Rest of World.
Market values are provided using 2017 as base year, 2018 as estimated
year, and 2023 as forecasted year. Estimated values used are based on
manufacturers’ total revenues. Projected and forecasted revenue values
are in constant U.S. dollars, unadjusted for inflation.
The report includes sections on the following topics:
-
- Current prevalence of colorectal cancer, trend analysis and factors
influencing future incidence - Market analysis by treatment type, including annual incidence and
trend analysis - Risk factors and other drivers that may impact the future incidence of
colorectal cancer - Review of the major market opportunities by identifying specific
high-growth and emerging market opportunities - Market share and information on key market players
- Analysis and forecast of the revenues for colorectal cancer treatment
for the global market, major market sub-segments subdivided by
geographic region and further, by selected country - Detailed review of the current products, their indications for all
identified market segments - Profile of the individual market sub-segments within the major market
segments analyzed and the distinguishing features of each of the
market sub-segments
- Current prevalence of colorectal cancer, trend analysis and factors
The report includes:
-
- 39 data tables and 18 additional tables
- Detailed overview of the colorectal cancer (CRC) therapeutics and
corresponding global markets - Country specific data and analysis for France, Germany, Italy, U.K.,
Spain, Russia, India, China, Japan, United States, Canada, Middle East
and Africa - Evaluation of market dynamics with a focus on increasing prevalence of
colorectal cancer cases, technological advancements in radiology and
chemotherapy, and increasing cancer prevention initiatives - Coverage of some of the significant CRC tests including CT
colonography, double-contrast barium enema, and biopsy test and their
usability study and future growth potential - A look into regulatory environment, new products launches and
technological advancements, and current strategies within the market - Company profiles of major manufacturers and suppliers of CRC
therapeutic drugs, including Abbott Laboratories, Bayer Healthcare,
GlaxoSmithKline, Merck & Co, Pfizer and Sanofi
Key Topics Covered
Chapter 1 Introduction
-
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
Chapter 2 Summary and Highlights
Chapter 3 Overview and Biology
-
- Introduction
- Market Definition and Overview
- Incidence
- Stages of Colorectal Cancer
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- Standard Treatment Options for Stage IV and Recurrent Colon Cancer
- Epidemiology of Colorectal Cancer
- Etiology
- Genetic Factors
- Environmental Factors
- Pathophysiology
- Risk Factors
- Inherited Syndromes
- Symptoms
- Metastasis
- Diagnosis
- Colonoscopy
- Biopsy
- Laboratory Tests
- CT Scan
- Magnetic Resonance Imaging (MRI)
- Ultrasound
- Others
- Prognosis
- Blockbuster Drugs
- Avastin
- Opdivo
- Cetuximab (Erbitux)
- End-Users
- Hospitals
- Cancer Research Laboratories
- Primary Healthcare and Community Health Centers
- Others
Chapter 4 Colorectal Cancer Market Dynamics
-
- Market Drivers
- Increasing Cancer Prevalence Rates
- Increasing Geriatric Population
- Outreach Programs Raise Cancer Awareness
- Cancer and Treatment Technologies
- Increasing Adoption of Combination and Targeted Therapies
- Market Restraints
- Drug Patent Expiries and Generic Drugs Emergence
- High Costs of The Screening Associated with The Drugs
- Lack of Awareness in Underdeveloped Countries
Chapter 5 Pipeline Analysis
-
- Research and Development Overview
- New Product Development
- Phase I Clinical Trials
- Phase II Clinical Trial
- Phase III Clinical Trials
- Impact on Market
Chapter 6 Global Colorectal Cancer Therapeutics Market Breakdown
by Treatment Type
-
- Market Size and Forecast
- Chemotherapy
- Overview
- Neoadjuvant Chemotherapy
- Adjuvant Chemotherapy
- Systemic Chemotherapy
- Regional Chemotherapy
- First-Line Chemotherapy and Targeted Therapy
- Side Effects
- Second-Line Chemotherapy
- Treatment of Liver Metastasis
- Market Size and Forecast
- Immunotherapy
- Overview
- Side Effects
- Market Size and Forecast
- Targeted Therapy
- Overview
- Targeted Chemotherapy Agents
- Monoclonal Antibody Therapy
- Tyrosine Kinase Inhibitors (TKIs)
- Side Effects
- Market Size and Forecast
- Conventional Treatment Options
- Surgery
Chapter 7 Global Colorectal Cancer Therapeutics Market Breakdown
by Region
-
- Introduction
- Market Size and Forecast
- North America
- Market Size and Forecast
- U.S.
- Canada
- Mexico
- Europe
- Market Drivers
- Market Restraints
- Market Size and Forecast
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Market Size and Forecast
- Market Drivers
- Market Restraints
- Japan
- India
- China
- Rest of Asia-Pacific
- Rest of World
- Market Size and Forecast
Chapter 8 Regulatory and Reimbursement Structure
-
- Overview of Regulations
- United States
- Canada
- Europe
- Japan
- China
- Overview of Pricing and Reimbursement
- United States
- Europe
- Japan
Chapter 9 Competitive Landscape and Key Developments
-
- Overview
- Bristol-Meyers Squibb
- Roche
- Key Developments, 2017-2019
- Mergers and Acquisitions
- New Product Launch
- Agreement, Collaboration and Partnerships
Chapter 10 Company Profiles
-
- Abbvie
- Abbott Laboratories
- Amgen
- Astrazeneca PLC
- Bayer Healthcare
- Bristol-Myers Squibb
- Eli Lilly and Co.
- F Hoffman-La Roche Ltd.
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/mrlv8n
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Colon
Cancer Drugs